Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Betaconnect, the first electronic autoinjector for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The autoinjector will be available for patients taking Betaseron (interferon beta-1b). After preparing Betaserson lyophilized powder, patients may administer the drug using Betaconnect with the specific syringes provided in the packaging. The autoinjector allows customizable injection speed and depth settings for quiet and precise injections. It also offers an optional back-up reminder function to alert patients when it is time for their next injection. The automatic needle insertion and retraction with a visual and audio end-of-dose indication informs patients when the injection is complete.

RELATED: Ocrelizumab: Promising Results for Primary Progressive MS

The immunomodulatory effects of interferon beta-1b include the enhancement of suppressor T cell activity, reduction of proinflammatory cytokine production, down-regulation of antigen presentation, and inhibition of lymphocyte trafficking into the central nervous system.

Betaseron is currently supplied as single-use vials in 5- or 14-count cartons. Betaconnect autoinjector is anticipated to be available starting in early 2016.

For more information call (888) 842-2937 or visit